Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/transcatheter-aortic-valve-leaflet-design-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape BriefTranscatheter Aortic Valve Leaflet Design Patents
- A long tail behind one clear leader. 19 companies appear in the ranking, with the leader at 12 records and a steep drop to 7 at fifth place and 5 by tenth.
- Filing has already peaked once. Annual filings rose to 14 in 2024, the high point so far in a dataset that runs from 2015 through mid-2026.
- Structure and sterilisation dominate the claim space. A61F implant/prosthesis claims cover 57.4% of the 61 records in scope and A61L sterilising/disinfecting claims cover 44.3%, leaving polymer chemistry classes far thinner.
61
Published Records
WO
Leading Jurisdiction
19
Active Filers Ranked
2024
Peak Filing Year
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this dataset covers
This landscape draws on 61 published records matching claims on transcatheter aortic valve leaflet design, spanning leaflet stress distribution, pericardial tissue thickness, geometry optimization, coaptation area, hydrodynamic performance and fatigue testing cycles. The scope runs from 2015 through a mid-2026 cut-off, so the most recent year is necessarily undercounted: publication typically lags filing by around 18 months, and 2026 shows zero filings only because those applications have not yet published.
Filers include large valve manufacturers, university research offices and single-institution filers working on leaflet geometry and tissue treatment. The IPC mix points to two separate technical conversations happening inside the same search string: one around the mechanical form of the leaflet and valve frame, and a second around the biomaterial and sterilisation chemistry used to treat pericardial tissue.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trends and technology composition
Two views of the same 61-record set: the year-by-year filing count, and the IPC subclasses those records are tagged with.
Filing trend, 2017-2026
Filings climbed from 3 in 2017 to a peak of 14 in 2024. Growth rate is not computable from fewer than four complete post-lag years, and 2026 is a partial year — treat the last one to two years as a floor, not a ceiling.
IPC subclass composition
A61F (implants & prostheses) and A61L (sterilising & disinfecting) together anchor the field, appearing in 57.4% and 44.3% of the 61 records respectively. Because a single record can carry several IPC codes, these shares sum to more than 100% and should be read against the 61-record total shown here, not against each other.
Shares are the percentage of the 61 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Transcatheter Aortic Valve Leaflet Design with Eureka
This page is one run against one query. Ask Eureka your own question about transcatheter aortic valve leaflet design and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Representative filing and most-cited prior art
Representative Record
US20200188094A1 — Optimization of replacement heart valve leaflets
COLORADO SEMINARY WHICH OWNS AND OPERATES THE UNIVERSITY OF DENVER
A method for optimizing a shape of a replacement valve leaflet, wherein the shape is determined by defining variable parameters that include a valve height, a leaflet coaptation height, and two sets of B-spline control points for planes of symmetry and tangency to the valve frame. The method creates iterations of potential leaflet shapes by varying these parameters using modeling software and calculating the resulting maximum stresses.Filed by the University of Denver's operating entity; abstract truncated to the claim scope relevant to leaflet geometry optimization.
Most-cited records in this set
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20120059487A1 | Biomaterials with enhanced properties and devices made therefrom | 115 |
| 2 | WO2019086958A1 | Expandable sealing skirt technology for leak-proof endovascular prostheses | 57 |
| 3 | EP2608815B1 | Biomaterials with enhanced properties and devices made therefrom | 47 |
| 4 | WO2018083493A1 | Annuloplasty prosthesis and related methods | 27 |
| 5 | US20200337837A1 | Expandable sealing skirt technology for leak-proof endovascular prostheses | 11 |
| 6 | US9095430B2 | Biomaterials with enhanced properties and devices made therefrom | 11 |
| 7 | US11622853B1 | Prosthetic heart valves | 6 |
| 8 | US20200188094A1 | Optimization of replacement heart valve leaflets | 6 |
| 9 | WO2023065048A1 | A doppler-based non-invasive computational diagnostic method for personalized cardiology | 4 |
| 10 | US11337798B2 | Optimization of replacement heart valve leaflets | 4 |
Citation counts reflect influence within the searched corpus and favour older filings; treat them as a signal of prior-art weight, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data implies for R&D and IP strategy
Three read-throughs from the filing pattern, the citation table and the IPC mix.
Concentration
12 vs 7 vs 5
leader / 5th / 10th place
One leader, then a fast drop-off
The leading assignee holds 12 records against 7 at fifth place and 5 by tenth, out of 19 ranked companies. That gap suggests one filer has built a genuine position on leaflet design specifically, while the rest of the field is spread across single-digit filers including several university offices.
Ranking covers 19 companies, not a top-50 or top-100 cut.
Citation weight
115 citations
top-cited record
Old biomaterials art still anchors the field
The most-cited record in this set, on biomaterials with enhanced properties, sits well ahead of the next tier at 57 citations. Both are foundational biomaterial patents rather than leaflet-geometry patents, meaning the geometry-specific claims here are still building citation weight of their own.
Citation counts favour older, more-searched records.
Filing shape
14 in 2024
peak filing year
Activity has not been linear
Filings rose from 3 in 2017 to a peak of 14 in 2024, but with fewer than four complete years once publication lag is stripped out, no reliable growth rate can be stated. Treat any apparent slowdown in the last one to two years as a publication-lag artefact, not evidence of a cooling field.
2026 figures are partial due to the mid-2026 data cut-off.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to transcatheter aortic valve leaflet design, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the claim space is still open
The ranked leaders sit alongside a long tail of single- and double-digit filers, several of them university research offices rather than device manufacturers.
Leader
12 records
top-ranked assignee
A device-focused leader with the deepest filing position
The top-ranked assignee's filing count is more than a third larger than the second tier, consistent with a company treating leaflet design as a defensible product line rather than a side claim on a broader valve patent.
Ranked among 19 companies in this dataset.
Academic cluster
co-assignee pairs at 5
strongest joint-filing links
University groups file jointly, not solo
Several of the strongest co-assignee pairs link medical schools and engineering departments, pointing to sponsored research programs rather than independent commercial filers. These groups tend to file on biomaterial treatment and geometry modeling rather than deployable device claims.
10 co-assignee pairs identified across the dataset.
Momentum
0 in latest year
across several tracked assignees
Recent-year activity has gone quiet across the board
Several previously active assignees, including one with a -100% year-on-year change, show zero filings in the latest tracked year. Given the roughly 18-month publication lag, this is more likely an artefact of the data cut-off than a genuine stop in R&D.
Momentum read against a mid-2026 cut-off; last year is undercounted.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Meril Life Sciences Pvt Ltd | 0 | — |
| SOUTHERN LIGHTS VENTURES 2002 | 0 | — |
| Anteris Technologies Corp | 0 | -100% |
| Endoluminal Sciences Pty Ltd | 0 | — |
| Baylor College of Medicine | 0 | — |
| Texas Heart Institute | 0 | — |
| William Marsh Rice University | 0 | — |
| North Carolina State University | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to next steps rather than final answers — each one narrows a decision a filing team actually has to make.
Map the leader's claim boundaries
With one assignee holding a clear lead in record count, the practical next step is reading its independent claims against the IPC subclasses it files in most, to see exactly how far its geometry or sterilisation claims reach.
Explore assignee claims in EurekaStress-test the white space chips
The under-claimed branches listed above are thin, not empty — a quick prior-art pull inside each one before drafting confirms whether the gap is real or just under-indexed in this search string.
Run a white-space search in EurekaRe-check the last 18 months separately
Because publication lag understates 2025-2026, any conclusion about a slowdown should be revisited once those years finish publishing rather than taken at face value now.
Track filing updates in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on this landscape
One assignee leads the ranked set with 12 records, well ahead of the fifth-place company at 7 and the tenth-place company at 5, across 19 ranked companies total. That gap indicates a genuine filing program rather than incidental coverage, though the ranking counts records, not granted claim scope, so it says nothing about how strong any individual patent is. Anyone doing freedom-to-operate work should read the leader's actual claims rather than relying on the count alone.
A61F (implants and prostheses) appears in 57.4% of the 61 records and A61L (sterilising and disinfecting) in 44.3%, making these the two dominant subclasses. Polymer composition classes (C08L, C08G) sit well behind at 14.8% and 13.1%, suggesting the chemistry side of leaflet treatment is less densely claimed than the mechanical and sterilisation side. Because records can carry multiple IPC codes, these percentages overlap and should not be added together.
Filings rose from 3 in 2017 to a peak of 14 in 2024, but there are fewer than four complete years once the roughly 18-month publication lag is accounted for, so no reliable growth rate can be stated from this data. The 2026 figure of zero is a data-cutoff artefact, not a sign the field has stopped. Anyone tracking momentum should revisit the 2024-2026 window once those years finish publishing.
This University of Denver filing claims a method for optimizing replacement valve leaflet shape using defined variable parameters, including valve height, leaflet coaptation height, and B-spline control points for planes of symmetry and tangency to the valve frame. It covers the modeling and iteration process itself, calculating maximum stresses across shape variants, rather than a specific physical leaflet geometry. A team pursuing a different modeling approach, or optimizing against a different variable set, may have room to design around it, but that requires a claim-by-claim read, not a summary.
Sub-areas such as pericardial tissue thickness gradients, fatigue-cycle test protocols, and sterilisation chemistry for laminate leaflet composites show thinner coverage than the dominant A61F and A61L classes in this dataset. This does not guarantee the space is open — it may simply be under-indexed by this search string — so a targeted prior-art pull inside each branch is the necessary next step before drafting. Treat these as leads for further search, not as confirmed gaps.
Answers are grounded in the same dataset. Derived from a Patsnap search on Transcatheter Aortic Valve Leaflet Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Transcatheter Aortic Valve Leaflet Design in depth with Eureka
Go past this page: query the whole transcatheter aortic valve leaflet design corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.